Mesoblast Limited (ASX:MSB)

Market Cap	2.79B
Revenue (ttm)	26.23M
Net Income (ttm)	-155.80M
Shares Out	1.28B
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,569,254
Average Volume	3,363,939
Open	2.360
Previous Close	2.420
Day's Range	2.110 - 2.370
52-Week Range	0.915 - 3.370
Beta	1.32
RSI	41.98
Earnings Date	Aug 27, 2025

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, whi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 73
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MSB

Financial Performance

In 2025, Mesoblast's revenue was $17.20 million, an increase of 191.39% compared to the previous year's $5.90 million. Losses were -$102.14 million, 16.1% more than in 2024.

Financial numbers in USD